Andreas Papapetropoulos, Stavros Topouzis, Steve P H Alexander, Miriam Cortese-Krott, Dave A Kendall, Kirill A Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A Panettieri, Hemal H Patel, Rainer Schulz, Barbara Stefanska, Gary J Stephens, Mauro M Teixeira, Nathalie Vergnolle, Xin Wang, Péter Ferdinandy
In 2023, seventy novel drugs received market authorization for the first time in either Europe (by the EMA and the MHRA) or in the United States (by the FDA). Confirming a steady recent trend, more than half of these drugs target rare diseases or intractable forms of cancer. Thirty drugs are categorized as "first-in-class" (FIC), illustrating the quality of research and innovation that drives new chemical entity discovery and development. We succinctly describe the mechanism of action of most of these FIC drugs and discuss the therapeutic areas covered, as well as the chemical category to which these drugs belong...
March 22, 2024: British Journal of Pharmacology